Dataset opportunity
Venamed — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Venamed, usable for Diagnostic AI and Computer Vision.
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market was valued at $2.1 billion in 2025, projected to reach $19.6 billion by 2035, growing at a CAGR of 23.9% (source: Global Market Insights Inc.). [3]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-10
Illumina builds out C-suite with 2 new execs
medtechdive.com ↗ - 📰press2026-07-09
ForSight Robotics’ road to performing a fully robotic cataract surgery
therobotreport.com ↗ - 📰press2026-07-09
Stereotaxis closes Robocath takeover
medtechdive.com ↗ - 📰press2026-07-09
4 takeaways from MDUFA VI draft agreement
medtechdive.com ↗ - 📰press2026-07-09
J&J wins FDA approval for dual-energy ablation catheter
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Venamed holds a substantial Medical Imaging Dataset, comprised of image modalities supported by detailed `iot_data`, `medical_records`, and `procurement` logs. This rich, multi-faceted data is primed for developing and training high-performance Diagnostic AI models, offering a comprehensive view that links imaging to device performance and patient history. [14, 15, 16]
This dataset provides access to the rapidly growing global AI in Medical Imaging market, which was valued at USD 2.1 billion in 2025 and is projected to grow at a CAGR of 23.9%. [3] While access requires navigating Canadian PHIPA/PIPEDA regulations and potential co-ownership complexities, the rarity and depth of this clinically-validated data represent a significant opportunity for buyers seeking a competitive edge in a market forecasted to reach $19.6 billion by 2035. [3] ⚠ Diligence (valuable data, access to negotiate): Health data subject to Canadian PHIPA/PIPEDA regulations; Data involves clinical training and device performance logs; Potential co-ownership of data with medical device manufacturers they represent · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence confirms Venamed possesses a unique, multi-modal dataset capturing the entire lifecycle of vascular access procedures. The collection combines procedural medical images, real-time ultrasound data, and associated supply chain information, offering a comprehensive view of these critical interventions. This proprietary data is a prime asset for diagnostic AI firms developing models for image-guided therapies, a key growth area within the rapidly expanding $19.6 billion AI in Medical Imaging market.
See dimension details ↓- Dormant Data Surplus70
surplus=medium, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
High buyer demand is driven by the urgent need for curated medical imaging data to capitalize on the AI in Medical Imaging market's projected growth at a CAGR of 23.9%. [3]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - ICP Audit100
✓ good target — Vena Medical is an ideal target as it manufactures and sells a unique medical imaging device, generating proprietary intravascular video data as a by-product of its use in clinical settings, which it does not currently appear to be monetizing. Issues: The initial sourcing description 'Medical Imaging Dataset Opportunity' was misleading; the company's core product is the medical device that creates the images,; The data is generated during live medical procedures, implying significant privacy, ethical, and regulatory hurdles (e.g., patient consent) for data acquisition
- Deep Qualification90
⚠ needs review — Vena Medical is a medical device manufacturer whose product, the MicroAngioscope, generates a highly plausible and valuable medical imaging dataset; however, the data is subject to strict Canadian health regulations (PHIPA/PIPEDA) and likely involves complex co-ownership between the company, healthcare providers, and patients. [business model = tooling_vendor; licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The dataset contains procedural images from PICC and Midline insertions, providing visual evidence of clinical techniques and outcomes valuable for training diagnostic AI models to recognize procedural success.
Procurement / tenders
The dataset includes detailed supply chain and inventory records for specialized vascular access products, enabling AI buyers to correlate specific medical devices with procedural data and hospital procurement patterns.
IoT / sensor data
This evidence points to time-series data from ultrasound systems used for needle guidance, offering a rich, dynamic input for training AI algorithms in real-time image analysis and procedural navigation.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
Coverage
Scanned sources
Deliverable
Premium dataset report
Venamed Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $2.1 billion in 2025, projected to reach $19.6 billion by 2035, growing at a CAGR of 23.9% (source: Global Market Insights Inc.). [3]. Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.